Publication
Title
Sterile pericarditis in Aachener minipigs as a model for atrial myopathy and atrial fibrillation
Author
Abstract
Atrial fibrillation (AF) is the most common arrhythmia caused by structural remodeling of the atria, also called atrial myopathy. Current therapies only target the electrical abnormalities and not the underlying atrial myopathy. For the development of novel therapies, a reproducible large animal model of atrial myopathy is necessary. This paper presents a model of sterile pericarditis-induced atrial myopathy in Aachener minipigs. Sterile pericarditis was induced by spraying sterile talcum and leaving a layer of sterile gauze over the atrial epicardial surface. This led to inflammation and fibrosis, two crucial components of the pathophysiology of atrial myopathy, making the atria susceptible to the induction of AF. Two pacemaker electrodes were positioned epicardially on each atrium and connected to two pacemakers from different manufacturers. This strategy allowed for repeated non-invasive atrial programmed stimulation to determine the inducibility of AF at specified time points after surgery. Different protocols to test AF inducibility were used. The advantages of this model are its clinical relevance, with AF inducibility and the rapid induction of inflammation and fibrosis-both present in atrial myopathy-and its reproducibility. The model will be useful in the development of novel therapies targeting atrial myopathy and AF.
Language
English
Source (journal)
Journal of visualized experiments. - -
Publication
2021
ISSN
1940-087X
DOI
10.3791/63094
Volume/pages
175 (2021) , p. 1-14
Article Reference
e63094
ISI
000708095700034
Pubmed ID
34633365
Medium
E-only publicatie
Full text (Publisher's DOI)
Full text (open access)
UAntwerpen
Faculty/Department
Research group
Project info
Neuregulin-1 as a therapy for atrial fibrillation and the role of the NRG-1/ErbB4 system in atrial remodelling.
Activating the neuregulin-1/ErbB4 pathway for treatment of heart failure.
Studies of the ErbB4 receptor in myocardial non-myocytes to create new opportunities for the treatment of cardiac disease.
I-PREDICT: Innovative Physiology-based pharmacokinetic model to pREdict Drug exposure In neonates undergoing Cooling Therapy.
Development of ErbB4 Agonists for Treatment of Heart Failure.
Infla-Med: Fundamental and translational research into targets for the treatment of inflammatory diseases.
Identification of small molecule ErbB4 agonist for treatment of heart failure, diabetic kidney injury and fibrotic disorders.
Defining atrial myopathy in aging and disease (DIAMOND consortium).
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identifier
Creation 08.11.2021
Last edited 02.10.2024
To cite this reference